BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 18812521)

  • 1. EGFRvIII expression and PTEN loss synergistically induce chromosomal instability and glial tumors.
    Li L; Dutra A; Pak E; Labrie JE; Gerstein RM; Pandolfi PP; Recht LD; Ross AH
    Neuro Oncol; 2009 Feb; 11(1):9-21. PubMed ID: 18812521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular mechanisms underlying effects of epidermal growth factor receptor inhibition on invasion, proliferation, and angiogenesis in experimental glioma.
    Guillamo JS; de Boüard S; Valable S; Marteau L; Leuraud P; Marie Y; Poupon MF; Parienti JJ; Raymond E; Peschanski M
    Clin Cancer Res; 2009 Jun; 15(11):3697-704. PubMed ID: 19435839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
    McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
    Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma.
    Kessler T; Sahm F; Blaes J; Osswald M; Rübmann P; Milford D; Urban S; Jestaedt L; Heiland S; Bendszus M; Hertenstein A; Pfenning PN; Ruiz de Almodóvar C; Wick A; Winkler F; von Deimling A; Platten M; Wick W; Weiler M
    Oncotarget; 2015 Oct; 6(31):31050-68. PubMed ID: 25682871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alteration of major vault protein in human glioblastoma and its relation with EGFR and PTEN status.
    Navarro L; Gil-Benso R; Megías J; Muñoz-Hidalgo L; San-Miguel T; Callaghan RC; González-Darder JM; López-Ginés C; Cerdá-Nicolás MJ
    Neuroscience; 2015 Jun; 297():243-51. PubMed ID: 25869624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of the type III epidermal growth factor receptor variant mutant receptor by dominant-negative EGFR-CD533 enhances malignant glioma cell radiosensitivity.
    Lammering G; Hewit TH; Holmes M; Valerie K; Hawkins W; Lin PS; Mikkelsen RB; Schmidt-Ullrich RK
    Clin Cancer Res; 2004 Oct; 10(19):6732-43. PubMed ID: 15475464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-grade glioma formation results from postnatal pten loss or mutant epidermal growth factor receptor expression in a transgenic mouse glioma model.
    Wei Q; Clarke L; Scheidenhelm DK; Qian B; Tong A; Sabha N; Karim Z; Bock NA; Reti R; Swoboda R; Purev E; Lavoie JF; Bajenaru ML; Shannon P; Herlyn D; Kaplan D; Henkelman RM; Gutmann DH; Guha A
    Cancer Res; 2006 Aug; 66(15):7429-37. PubMed ID: 16885338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The protein phosphatase activity of PTEN regulates SRC family kinases and controls glioma migration.
    Dey N; Crosswell HE; De P; Parsons R; Peng Q; Su JD; Durden DL
    Cancer Res; 2008 Mar; 68(6):1862-71. PubMed ID: 18339867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pten signaling in gliomas.
    Knobbe CB; Merlo A; Reifenberger G
    Neuro Oncol; 2002 Jul; 4(3):196-211. PubMed ID: 12084351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ionizing radiation enhances matrix metalloproteinase-2 secretion and invasion of glioma cells through Src/epidermal growth factor receptor-mediated p38/Akt and phosphatidylinositol 3-kinase/Akt signaling pathways.
    Park CM; Park MJ; Kwak HJ; Lee HC; Kim MS; Lee SH; Park IC; Rhee CH; Hong SI
    Cancer Res; 2006 Sep; 66(17):8511-9. PubMed ID: 16951163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib.
    Haas-Kogan DA; Prados MD; Tihan T; Eberhard DA; Jelluma N; Arvold ND; Baumber R; Lamborn KR; Kapadia A; Malec M; Berger MS; Stokoe D
    J Natl Cancer Inst; 2005 Jun; 97(12):880-7. PubMed ID: 15956649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glioma stem cells are more aggressive in recurrent tumors with malignant progression than in the primary tumor, and both can be maintained long-term in vitro.
    Huang Q; Zhang QB; Dong J; Wu YY; Shen YT; Zhao YD; Zhu YD; Diao Y; Wang AD; Lan Q
    BMC Cancer; 2008 Oct; 8():304. PubMed ID: 18940013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines.
    Festuccia C; Muzi P; Millimaggi D; Biordi L; Gravina GL; Speca S; Angelucci A; Dolo V; Vicentini C; Bologna M
    Endocr Relat Cancer; 2005 Dec; 12(4):983-98. PubMed ID: 16322337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Could changes in the regulation of the PI3K/PKB/Akt signaling pathway and cell cycle be involved in astrocytic tumor pathogenesis and progression?
    Hlobilkova A; Ehrmann J; Sedlakova E; Krejci V; Knizetova P; Fiuraskova M; Kala M; Kalita O; Kolar Z
    Neoplasma; 2007; 54(4):334-41. PubMed ID: 17822324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of Wnt5a in the proliferation of human glioblastoma cells.
    Yu JM; Jun ES; Jung JS; Suh SY; Han JY; Kim JY; Kim KW; Jung JS
    Cancer Lett; 2007 Nov; 257(2):172-81. PubMed ID: 17709179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New anti-cancer chemicals Ertredin and its derivatives, regulate oxidative phosphorylation and glycolysis and suppress sphere formation in vitro and tumor growth in EGFRvIII-transformed cells.
    Atsumi S; Nosaka C; Adachi H; Kimura T; Kobayashi Y; Takada H; Watanabe T; Ohba S; Inoue H; Kawada M; Shibasaki M; Shibuya M
    BMC Cancer; 2016 Jul; 16():496. PubMed ID: 27431653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isolation and partial characterization of a new human glioblastoma cell line.
    Brehar FM; Bleotu C; Stefan LM; Buzgariu W; Chivu M; Utoiu E; Matei L; Ciurea AV; Tascu A
    Chirurgia (Bucur); 2009; 104(4):453-61. PubMed ID: 19886054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway.
    de la Iglesia N; Konopka G; Puram SV; Chan JA; Bachoo RM; You MJ; Levy DE; Depinho RA; Bonni A
    Genes Dev; 2008 Feb; 22(4):449-62. PubMed ID: 18258752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protein phosphatase activity of PTEN inhibited the invasion of glioma cells with epidermal growth factor receptor mutation type III expression.
    Cai XM; Tao BB; Wang LY; Liang YL; Jin JW; Yang Y; Hu YL; Zha XL
    Int J Cancer; 2005 Dec; 117(6):905-12. PubMed ID: 15986432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rarity of PTEN deletions and EGFR amplification in malignant gliomas of childhood: results from the Children's Cancer Group 945 cohort.
    Pollack IF; Hamilton RL; James CD; Finkelstein SD; Burnham J; Yates AJ; Holmes EJ; Zhou T; Finlay JL;
    J Neurosurg; 2006 Nov; 105(5 Suppl):418-24. PubMed ID: 17328268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.